Bison Wealth’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $1.93M | Sell |
10,881
-8,460
| -44% | -$1.56M | 0.43% | 53 |
|
|
2024
Q3 | $3.82M | Buy |
19,341
+671
| +4% | +$125K | 0.61% | 34 |
|
|
2024
Q2 | $3.4M | Hold |
18,670
| – | – | 0.55% | 39 |
|
|
2024
Q1 | $3.4M | Buy |
18,670
+3,568
| +24% | +$615K | 0.55% | 39 |
|
|
2023
Q4 | $2.34M | Buy |
15,102
+42
| +0.3% | +$6.12K | 0.41% | 59 |
|
|
2023
Q3 | $2.24M | Sell |
15,060
-72
| -0.5% | -$10.6K | 0.44% | 54 |
|
|
2023
Q2 | $2.04M | Buy |
15,132
+3,132
| +26% | +$459K | 0.38% | 65 |
|
|
2023
Q1 | $1.76M | Sell |
12,000
-732
| -6% | -$112K | 0.55% | 54 |
|
|
2022
Q4 | $1.85M | Sell |
12,732
-1,393
| -10% | -$214K | 0.59% | 50 |
|
|
2022
Q3 | $1.9M | Buy |
14,125
+381
| +3% | +$54.7K | 0.74% | 33 |
|
|
2022
Q2 | $2.1M | Buy |
13,744
+1,767
| +15% | +$270K | 1.21% | 21 |
|
|
2022
Q1 | $1.94M | Buy |
11,977
+2,957
| +33% | +$430K | 0.99% | 22 |
|
|
2021
Q4 | $1.22M | Buy |
9,020
+1,192
| +15% | +$141K | 0.71% | 31 |
|
|
2021
Q3 | $844K | Sell |
7,828
-182
| -2% | -$20.8K | 0.39% | 63 |
|
|
2021
Q2 | $902K | Buy |
8,010
+424
| +6% | +$47.8K | 0.39% | 60 |
|
|
2021
Q1 | $606K | Buy |
7,586
+2,208
| +41% | +$236K | 0.26% | 93 |
|
|
2020
Q4 | $576K | Sell |
5,378
-173
| -3% | -$16.6K | 0.27% | 88 |
|
|
2020
Q3 | $486K | Sell |
5,551
-363
| -6% | -$34.2K | 0.29% | 91 |
|
|
2020
Q2 | $581K | Buy |
5,914
+691
| +13% | +$60.8K | 0.37% | 69 |
|
|
2020
Q1 | $398K | Sell |
5,223
-216
| -4% | -$18.4K | 0.29% | 97 |
|
|
2019
Q4 | $482K | Sell |
5,439
-41
| -0.7% | -$3.4K | 0.23% | 116 |
|
|
2019
Q3 | $415K | Buy |
5,480
+707
| +15% | +$48.5K | 0.23% | 119 |
|
|
2019
Q2 | $347K | Sell |
4,773
-246
| -5% | -$19.3K | 0.2% | 140 |
|
|
2019
Q1 | $405K | Buy |
5,019
+776
| +18% | +$63.5K | 0.25% | 125 |
|
|
2018
Q4 | $391K | Hold |
4,243
| – | – | 0.28% | 102 |
|
|
2018
Q3 | $401K | Sell |
4,243
-862
| -17% | -$81.7K | 0.26% | 114 |
|
|
2018
Q2 | $473K | Buy |
5,105
+154
| +3% | +$15K | 0.35% | 80 |
|
|
2018
Q1 | $469K | Buy |
4,951
+1,187
| +32% | +$130K | 0.36% | 79 |
|
|
2017
Q4 | $364K | Sell |
3,764
-500
| -12% | -$47.1K | 0.27% | 102 |
|
|
2017
Q3 | $379K | Sell |
4,264
-1,081
| -20% | -$82.3K | 0.3% | 94 |
|
|
2017
Q2 | $388K | Sell |
5,345
-117
| -2% | -$7.87K | 0.32% | 86 |
|
|
2017
Q1 | $356K | Buy |
5,462
+39
| +0.7% | +$2.45K | 0.31% | 94 |
|
|
2016
Q4 | $340K | Sell |
5,423
-46
| -0.8% | -$2.81K | 0.29% | 96 |
|
|
2016
Q3 | $345K | Sell |
5,469
-1,964
| -26% | -$127K | 0.29% | 91 |
|
|
2016
Q2 | $456K | Buy |
7,433
+521
| +8% | +$31.7K | 0.27% | 110 |
|
|
2016
Q1 | $391K | Sell |
6,912
-2,348
| -25% | -$131K | 0.25% | 114 |
|
|
2015
Q4 | $543K | Sell |
9,260
-368
| -4% | -$21.2K | 0.31% | 102 |
|
|
2015
Q3 | $519K | Buy |
9,628
+348
| +4% | +$22.7K | 0.34% | 98 |
|
|
2015
Q2 | $619K | Buy |
9,280
+1,215
| +15% | +$79.3K | 0.36% | 93 |
|
|
2015
Q1 | $472K | Sell |
8,065
-4,817
| -37% | -$291K | 0.29% | 117 |
|
|
2014
Q4 | $843K | Buy |
+12,882
| New | +$812K | 0.64% | 44 |
|
Other funds holding ABBV
Bison Wealth's ABBV Position: Q4 2024 in Review
Bison Wealth reduced its AbbVie (ABBV) stake by 44% in Q4 2024, selling an estimated $1.56M and leaving 10,881 shares worth $1.93M. The position accounts for 0.43% of the portfolio, ranked #53.
Bison Wealth first reported a position in ABBV in Q4 2014 and has held it in 41 quarters since. The position peaked at $3.82M in Q3 2024. 3,745 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.
- Bison Wealth held 10,881 shares of AbbVie worth $1.93M as of Q4 2024.
- Bison Wealth sold 8,460 AbbVie shares in Q4 2024, an estimated $1.56M.
- AbbVie made up 0.43% of Bison Wealth's portfolio in Q4 2024, its #53 holding.
- Bison Wealth first reported a position in AbbVie in Q4 2014 and has held it in 41 quarters since.
- Bison Wealth's AbbVie position peaked at $3.82M in Q3 2024.
- 3,745 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.
Based on Bison Wealth's 13F filing for Q4 2024, filed 14 Feb 2025.